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Abstract
Results of randomised controlled trials of tight glycaemic control in hospital inpatients might vary
with population and disease state. Individualised therapy for different hospital inpatient
populations and identification of patients at risk of hyperglycaemia might be needed. One risk
factor that has received much attention is the presence of pre-existing diabetes. So-called stress
hyperglycaemia is usually defined as hyperglycaemia resolving spontaneously after dissipation of
acute illness. The term generally refers to patients without known diabetes, although patients with
diabetes might also develop stress hyperglycaemia—a fact overlooked in many studies comparing
hospital inpatients with or without diabetes. Investigators of several studies have suggested that
patients with stress hyperglycaemia are at higher risk of adverse consequences than are those with
pre-existing diabetes. We describe classification of stress hyperglycaemia, mechanisms of harm,
and management strategies.
Introduction
Transient hyperglycaemia during severe illness in adult patients without known diabetes was
thought to be harmless or even advantageous. However, results of a large randomised
controlled trial1 showed clear mortality benefits from intensive insulin therapy for patients
in intensive care units (ICUs), irrespective of whether a previous diagnosis of diabetes had
been made. Subsequent reports2–8 in mixed medical and surgical ICUs have tempered initial
enthusiasm for strict glycaemic control, mainly because of an unacceptable risk of
hypoglycaemia. Such findings have triggered appeals for focused efforts to identify patients
who are at high risk of hyperglycaemia-mediated harm and likely to benefit from
interventions.9
Investigators of several studies suggest that patients with stress hyperglycaemia and no
previous diagnosis of diabetes face worse consequences at a given severity of
hyperglycaemia than do those with pre-existing diabetes. We describe challenges in
identification and diagnosis of such patients, analyse the evidence that lends support to the
harms of stress hyperglycaemia, review the unique causal features and proposed
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mechanisms of harm of stress hyperglycaemia, suggest management strategies, and identify
areas of future study. We intend not to diminish the importance of pre-existing diabetes or
chronic glycaemic control, but to draw attention to the adverse consequences or concomitant
effects of acute hyperglycaemia.
Diagnosis
Stress hyperglycaemia generally refers to transient hyperglycaemia during illness and is
usually restricted to patients without previous evidence of diabetes. For the purpose of this
Seminar, we will discuss physical—rather than psychological—stress. However, the
identification of such patients is complex. No guidelines specifically define stress
hyperglycaemia. In a technical review written by the Diabetes in Hospitals Writing
Committee of the American Diabetes Association (ADA),10 patients are classified into one
of three groups—known diabetes, newly diagnosed diabetes, and hospital-related
hyperglycaemia (panel). This classification needs information from hospital follow-up that
is not usually available. Change in glucose from baseline and not the absolute glucose
concentration might be of value, irrespective of whether a patient has pre-existing diabetes
(figure 1). Thus, we propose two diagnostic categories of stress hyperglycaemia—hospital-
related hyperglycaemia according to the ADA consensus definition (fasting glucose >6·9
mmol/L or random glucose >11·1 mmol/L without evidence of previous diabetes), and pre-
existing diabetes with deterioration of preillness glycaemic control. The most appropriate
cutoff point for stress hyperglycaemia in patients with pre-existing diabetes needs to be
established, but certainly a patient with a well controlled (<7%) glycosylated haemoglobin
(HbA1c) whose glucose concentration is consistently higher than the threshold defined for
hospital-related hyperglycaemia would qualify.
30% of people who have diabetes in the USA are unaware of their status11 and, therefore,
many hospital inpatients with apparent stress hyperglycaemia have underlying diabetes or
prediabetes (table).12–18 In an undifferentiated hospital population, results from a small
study18 showed that 60% of patients with admission hyperglycaemia had confirmed diabetes
at 1 year. Another study showed that nearly one in five adult inpatients had probable
unrecognised diabetes—identified by an admission HbA1c higher than 6·1%.19 In this study,
random glucose concentrations poorly predicted elevated HbA1c, indicating the need for
more sophisticated diagnostic criteria than are available.
Epidemiology
Poor outcomes related to stress hyperglycaemia
Researchers of intravenous insulin therapy have not specifically compared patients with and
without stress hyperglycaemia in prospective controlled studies.1–6 Other investigators20
exclude patients without known diabetes altogether. With the exception of a few randomised
trials, most data are observational and drawn from ICUs or patients with acute myocardial or
cerebrovascular events. One retrospective review21 of 1886 unselected hospital inpatients
was stratified according to whether patients had normoglycaemia, pre-existing diabetes, or
newly diagnosed hyperglycaemia (fasting glucose >7 mmol/L or random glucose >11·1
mmol/L on two separate occasions). Compared with patients with normoglycaemia, after
adjustment for age, body-mass index, sex, hyper tension, coronary artery disease, infection,
renal failure, and ICU admission, mortality was 18·3 times higher in patients with newly
diagnosed hyperglycaemia (p<0·05), but only 2·7 times higher in those with known diabetes
(p<0·05). This study did not distinguish between a new diagnosis of diabetes and transient
stress hyperglycaemia.
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However, a relation between short-term glycaemic control and hospital outcomes has been
identified.19 Patients with hyperglycaemia without known diabetes who were critically
ill22–26 or had acute coronary or cerebro-vascular1,13,27–32 events were shown to have
increased risk of mortality, although patients who were hyperglycaemic with known
diabetes did not. Increased mortality was also reported in hyperglycaemic inpatients with or
without diabetes who had acute myocardial infarction or acute coronary syndrome,33–40 or
cerebrovascular accident.41 Other studies41–45 reported no rise in risk related to
hyperglycaemia in inpatients in ICUs, or in patients with acute coronary syndrome, or
cerebrovascular accident.
Stress hyperglycaemia in ICUs
In posthoc analysis, data from a large randomised controlled trial46 of intensive insulin
therapy in a surgical ICU suggest that patients with a previous diagnosis of diabetes were at
lower risk of mortality than were those without or newly diagnosed with diabetes (odds ratio
[OR] 0·356, 95%CI 0·158–0·803, p=0·01). Posthoc analysis of the counterpart to this study
in a medical ICU showed a reduction in mortality only in patients needing an ICU stay of 3
days or longer, and seemingly only in patients with newly discovered hyperglycaemia
(11·5% reduction in mortality in patients with new hyperglycaemia vs 1·8% increase in
mortality with those with known diabetes).2 In a pooled analysis of both trials, patients with
diabetes achieved no survival benefit, although the number of patients with known diabetes
was small.22
In other randomised studies,3,6,8 results were stratified according to the presence of pre-
existing diabetes. Investigators of a small (n=523)6 single-centre study reported no benefit
of intensive intravenous insulin therapy with a mean glucose target of 4·4–6·1 mmol/L
compared with a target of 10–11·1 mmol/L. This study was powered to detect an 8%
absolute risk reduction. No difference in outcomes between patients with or without diabetes
was identified. Investigators of a multicentre randomised controlled study of patients with
sepsis noted outcomes did not differ between those with or without diabetes treated with
intensive insulin therapy. However, this study was stopped before enrolment was completed
largely because of frequent hypoglycaemia.3
A pivotal, large, multicentre randomised controlled trial (NICE-SUGAR)8 comparing
conventional (<10 mmol/L) versus tight (4·5–6·0 mmol/L) glycaemic control using
intravenous insulin infusions in ICU patients showed increased mortality for patients in the
intensive arm (OR 1·14, 95% CI 1·02–1·28, p=0·02). The treatment effect did not differ
between surgical and non-surgical patients, nor was a difference observed between patients
with or without known diabetes.
Other non-randomised or observational studies provide less robust data than does the NICE-
SUGAR trial, but deserve mention because they attempt to identify patients with stress
hyperglycaemica. In a mixed surgical (n=676), medical (n=1856), and trauma (n=134) ICU,
outcomes in patients with diabetes (n=532) were compared with those in patients without
known diabetes after implementation of a moderately tight glycaemic control protocol
(target blood glucose concentrations 6·9 mmol/L).42 Mortality was significantly reduced in
non-diabetic patients but not in those with known diabetes. Furthermore, in patients without
diabetes, mortality began to rise when mean glucose concentration exceeded 7·8 mmol/L in
patients without diabetes, whereas in patients with diabetes this threshold was 10 mmol/L.
Several observational studies have assessed whether patients with stress hyperglycaemia
have a high risk of poor outcomes. A large observational study of 728 patients with diabetes
and 4218 patients without diabetes established that at any mean ICU glucose concentration,
ICU (but not hospital) mortality is greater (up to nearly four times) in patients without
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diabetes than in those with the disorder,23 even after adjustment for disease severity (Acute
Physiology and Chronic Health Evaluation II score). In a mixed ICU sample of 2826
patients, those without diabetes who needed treatment for hyperglycaemia had higher
sequential organ failure assessment (SOFA) scores, greater hospital length of stay (8·0 vs 6·7
days, p<0·001), and higher mortality rates (10% vs 6%, p<0·01) than did patients with
known diabetes, despite lower median glucose and adjustment for severity of illness and
other covariates.24 By contrast, patients with the disorder had the same death rate as
normoglycaemic non-diabetic patients (6% vs 5%), despite higher SOFA scores and median
glucose values. The high mortality rate in hyperglycaemic patients without known diabetes
and absence of relation of hyperglycaemia to mortality in patients with diabetes was also
reported in mixed ICU populations25 and in those with severe sepsis.26 However, not all
results from ICU studies show a high risk of mortality related to acute hyperglycaemia.43
Cardiovascular disease and stroke
The relation between newly discovered hyperglycaemia and mortality in patients presenting
with acute myocardial infarction or acute coronary syndrome has been investigated.
Unfortunately, most studies rely on glucose concentrations at admission to identify stress
hyperglycaemia. In a meta-analysis,47 the pooled unadjusted relative risk (RR) of in-hospital
mortality after myocardial infarction in 1856 patients without diabetes who had stress
hyperglycaemia at admission was 3·9 (95% CI 2·9–5·4) compared with normoglycaemic
non-diabetic patients. By comparison, the risk of death in 688 hyper glycaemic patients with
diabetes was 1·7 (95% CI 1·2–2·4) relative to normoglycaemic patient with diabetes.
Other studies support these findings. In more than 160 000 patients admitted with acute
myocardial infarction, glucose concentration at admission was associated with a steep rise in
30-day mortality for those without known diabetes: for glucose concentrations of 6·1–7·8
mmol/L on admission, OR 1·17, (95% CI 1·11–1·24); 13·3 mmol/L or more, OR 1·87, (95%
CI 1·75–2·00).48 However, for patients with established diabetes, mortality rose only at the
highest glucose concentration (>13·3 mmol/L OR 1·32, 95% CI 1·17–1·50). Discrepancies
between studies might be explained in part by the length of follow-up—the association
between diabetes status and mortality strengthened as the length of follow-up increased.
With longer follow-up, the assocation between diabetes and mortality was significant, but
the association with stress hyperglycaemia became non-significant.33,34
Another study26 investigated the role of acute and chronic hyperglycaemia in 827 patients
with diabetes, 324 of whom had at least two HbA1c measurements in the previous 2 years.
Glucose concentrations at admission in the third (2·84 mmol/L,95% CI 1·04–7·76, p=0·04)
or fourth (5·03 mmol/L, 95% CI 1·90–13·26, p=0·001) quartiles independently predicted
inhospital mortality after acute myocardial infarction. However, mortality did not differ
much between quartiles of HbA1c. Results of another study49 confirmed no association
between mortality and HbA1c, thus drawing attention to the potential importance of acute
hyperglycaemia over chronic hyperglycaemia in hospital inpatients with acute myocardial
infarction.
A retrospective analysis50 of 433 patients after stroke established that blood glucose
concentrations higher than 10 mmol/L at admission (OR=2·1, 95% CI 1·1–4·6, p=0·02), but
not diabetes itself, was an independent predictor of dependency 1 year after first-ever stroke.
A meta-analysis51 showed that in patients without diabetes, stress hyperglycaemia
(definition varied by study) was associated with a high risk of mortality after stroke (pooled
RR 3·07, 95% CI 2·50–3·79). However, this was not true for patients with diabetes (pooled
RR 1·30, 95% CI 0·49–3·43). In further studies,31,32,52 Glucose concentration on admission
was associated with higher mortality rates in patients without a history of diabetes than in
Dungan et al. Page 4













those with a history of diabetes—both for ischaemic stroke and intracranial haemorrhage.
This finding was not confirmed in another study.45
In a prospective observational analysis43 of 262 patients with stroke, researchers used a
normal fructosamine and to identify those with transient hyperglycaemia. HbA1c Patients
with transient hyperglycaemia had worse stroke severity scores than did those with either
known diabetes or normoglycaemia. Furthermore, 30-day mortality was higher in patients
with transient hyperglycaemia than in those with normoglycaemia (27·4% vs 12·7%,
p=0·01), but no significant difference between patients with diabetes (16·2%) and
normoglycaemia was reported.
Surgery
The first Leuven study1 consisted largely of postsurgical patients, two-thirds of whom had
cardio thoracic surgery. Because patients with no history of diabetes benefited most from
intensive insulin therapy, the same could be true for the subset of post cardiothoracic surgery
patients. However, a prospective study20 with historical controls showed reductions in
mortality, hospital length of stay, and surgicalsite infections after cardiothoracic surgery in
patients with diabetes who received intensive insulin therapy. By contrast with the Leuven
study, in the Furnary study53 patients with transient hyperglycaemia were excluded,
indicating that patients with diabetes also benefit from glycaemic control. This finding
seems to be in agreement with another study.54
Chronic hyperglycaemia in the perioperative setting also seems to be harmful, affecting the
rate of postoperative infections and neurological outcomes.55,56 A meta-analysis57 of 34
trials showed that perioperative insulin infusion reduces mortality but increases rates of
hypoglycaemia. However, researchers calculated that the available mortality data were too
few to reliably detect a plausible treatment effect, and that the presence of diabetes did not
affect outcomes. Thus, hyperglycaemia in patients with or without diabetes could adversely
affect outcomes after surgery.
Stress hyperglycaemia is linked to poor outcomes and the association seems to be stronger
for patients without diabetes than for those with pre-existing diabetes. However, studies
were not prospectively designed to compare patients with stress hyperglycaemia and pre-
existing diabetes, creating some limitations. Despite data from interventional studies1,2 and
controlling for severity of illness, residual confounding could be difficult to completely
eliminate. For example, patients with pre-existing diabetes might be more likely to undergo
glycaemic monitoring and receive insulin treatment25 or other life-saving drugs58 in the
hospital than would undiagnosed patients. Additionally, studies lack a consistent or strict
definition of stress hyperglycaemia.47,51
Many studies do not have sufficient comparator groups because they are observational. For
example, direct comparisons of glycaemic control in non-diabetic patients who have stress
hyperglycaemia with diabetic patients are often unable to account for the change in glucose
from baseline in the latter. Non-diabetic patients with stress hyperglycaemia should ideally
be compared with those who have been diagnosed and who have deterioration of pre-illness
glycaemic control to enable assessment of whether outcomes differ. However, results of a
few studies27,40,49 show poor outcomes that persist in patients with newly discovered
hyperglycaemia, after accounting for glycaemic control. Despite these limitations, results of
controlled studies seem to show that treatment of hyperglycaemia in patients improves
outcomes, although new data indicate that the quest for strict normoglycaemia is harmful.
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In the hospital setting, a combination of factors affect the development of stress
hyperglycaemia (figure 2). The mechanisms for this disorder probably vary with the
patients’ underlying glucose tolerance, type and severity of disease, and stage of illness. The
cause of hyperglycaemia in type 2 diabetes is a combination of insulin resistance and β-cell
secretory defects. However, the development of stress hyperglycaemia is caused by a highly
complex interplay of counter-regulatory hormones such as catecholamines, growth hormone,
cortisol, and cytokines (figure 3).34,59,60 The underlying illness might affect the scale of
cytokine production and hormonal derangements. Complex feedforward and feedback
mechanisms between hormones and cytokines exist,61 and this neurohormonal environment
ultimately leads to excessive hepatic glucose production and insulin resistance.59,60 High
hepatic output of glucose, especially through gluconeogenesis, seems to be the most
important contributor to stress hyperglycaemia.62,63 Excessive glucagon is the primary
mediator of gluconeogenesis,64 although epinephrine65 and cortisol66 also contribute.
Tumour necrosis factor-α (TNFα) might promote gluconeogenesis by stimulating glucagon
production.67
Insulin resistance during illness is characterised by an inability to suppress central hepatic
glucose production. In the periphery, insulin resistance is mediated through two major
pathways. Reduced insulin-mediated glucose uptake results from defects in postreceptor
insulin signalling68 and downregulation of glucose transporter (GLUT)-4.69 Additionally,
impaired non-oxidative glucose disposal probably results from reduced skeletal muscle
glycogen synthesis.70 Both excess cortisol71 and epinephrine72 reduce insulin-mediated
glucose uptake. Cytokines such as TNFα,73 and interleukin 174 inhibit postreceptor insulin
signalling. Severity of illness is associated with a proportional rise in serum cytokines25 and
insulin resistance.75 Furthermore, hyperglycaemia exacerbates the cytokine, inflammatory,
and oxidative stress response, potentially setting up a vicious cycle whereby hyperglycaemia
leads to further hyperglycaemia.76–78 Resolution of hyperglycaemia is associated with
normalisation of the inflammatory response.78
Insulin resistance ultimately promotes a catabolic state in which lipolysis takes place.
Excessive circulating free fatty acids in turn exacerbate insulin resistance by disrupting end-
organ insulin signalling79 and glycogen synthase.80 This lipotoxicity aggravates the
inflammatory state, paralleling the effects of glucotoxicity.81 Glucotoxicity, lipotoxicity, and
inflammation are key components of what might be viewed as an exaggerated global
insulin-resistance syndrome associated with acute illness. These components also promote
endothelial dysfunction, which has a complex reciprocal cause–effect relation with insulin
resistance.82 Hyperinsulinaemia might impart additive consequences to that of
hyperglycaemia, including exaggerated inflammatory and counter-regulatory hormone
responses and impaired fibrinolysis.83,84
Despite reduced insulin-mediated glucose uptake, an early increase in whole-body glucose
uptake takes place—mainly as a result of cytokine-mediated up regulation of GLUT-1.85–88
GLUT-1 is a ubiquitous glucose transporter that is involved in non-insulin-mediated glucose
uptake. Although non-oxidative metabolism (eg, glycogen synthesis) is impaired, oxidative
glucose metabolism is upregulated early.89 In addition to patient-specific factors, certain
therapeutic interventions such as catecholamine infusions, corticosteroids, and enteral and
parenteral nutrition can worsen or precipitate hyperglycaemia.25 No studies of mechanisms
comparing critically ill patients with diabetes or stress hyperglycaemia are available.
Therefore, whether differences in pathophysiology explain differences in outcomes is
unclear.
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Mechanism of adverse outcomes
The typical chronic complications of diabetes take several years to develop; therefore, the
explanation for a rise in harm that is related to stress hyperglycaemia needs further
consideration (figure 4). Stress hyperglycaemia is mediated by much greater inflammatory
and neuroendocrine derangements than are expected in chronic hyperglycaemia associated
with diabetes. Possibly, these derangements heighten susceptibility to benefits of
interventions. For example, multiorgan failure is associated with widespread microvascular
endothelial dysfunction, and improved outcomes associated with intensive insulin therapy
have been attributed in part to endothelial protection.90
Some evidence suggests that chronic hyperglycaemia sets up a pattern of cellular
conditioning that might actually be protective of acute hyperglycaemia-mediated damage
during critical illness. One mechanism for this effect might be the preferential
downregulation of glucose transporters under conditions of chronic rather than intermittent
hyperglycaemia. GLUT-1 and GLUT-3 are facilitative glucose transporters that allow
glucose to enter cells independently of insulin. Several factors that upregulate these
transporters are elaborated during critical illness, potentially allowing glucose to enter cells
unchecked by normal downregulatory responses.91 Thus, a wide range of tissues might be
susceptible to enhanced glucose toxicity as a result of acute illness.91,92 Whether patients
with chronic hyperglycaemia are able to compensate by downregulating glucose transporters
is unknown. Various oxidative stressors prevent the downregulation of GLUT-1 transporters
in vascular endothelial cells.93
Acute fluctuations in glucose concentrations are associated with mortality in acutely ill
patients, independently of mean glucose concentration.94–97 Repetitive acute glucose
fluctuations induce more endothelial apoptosis,98 and greater endothelial dysfunction and
oxidative stress responses compared with the less variable excursions both in vitro98,99 and
in patients with or without known diabetes.100,101 Furthermore, oxidative stress seems to
have a unifying causal role in the stimulation of classic intracellular pathways that mediate
chronic complications of hyperglycaemia.102 Therefore, increased oxidative stress during
acute hyperglycaemia (by contrast with chronic hyperglycaemia or diabetes) would seem to
be a plausible mechanism for additive adverse effects of stress hyperglycaemia.
Pre-existing microvascular and macrovascular disease in patients with diabetes might affect
outcomes associated with strict glycaemic control. For example, patients with diabetic
autonomic dysfunction might be predisposed to development of severe hypoglycaemia as a
result of hypoglycaemia unawareness. Patients with cardiac autonomic dysfunction might be
predisposed to development of arrythmias as a result of hypoglycaemia. Furthermore, the
response to hypoglycaemia could be more severe in patients with previous evidence of
diabetes who have pre-existing endothelial dysfunction and greater tendency for ischaemic
events than in those without diabetes.103 Hypoglycaemia elicits a counter-regulatory
hormonal response that might aggravate the inflammatory state already present in acute
illness. Whether hypoglycaemia is an independent indicator of overall risk of death, or
merely a marker of severity of illness is unclear.104,105 In patients with severe brain injury,
changes in glucose transport might in part account for an association of tight glycaemic
control with abnormal cerebral glucose metabolism and poor outcomes.106 Conversely, in
the Leuven studies,21 a low propensity for hypoglycaemia does not by itself explain any
susceptibility to benefits of glucoregulation.
Management
Current guidelines107,108 do not recognise stress hyperglycaemia as being different from
pre-existing diabetes, although such guidelines might specify separate targets for ICU and
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non-ICU patients. Other than the distinction between surgical and medical ICU patients,
insufficient data are available to recommend risk stratification for assignment of glucose
targets with respect to the cause or severity of hyperglycaemia. However, some investigators
have noted that the concept of separate targets is similar to other situations, in which rapid
correction of longstanding physiology is detrimental.22 Guidelines are being revised in
response to the NICE-SUGAR results. We emphasise that providers “should not abandon
glucose management in the ICU setting, but that a less intensive target similar to that of the
conventional treatment arm (mean glucose 8 mmol/L) be implemented”.109,110 Outside of
the ICU, no inpatient data exist to guide treatment decisions, but individualised glucose
targets based on outpatient recommendations are reasonable.107,108
No studies have specifically investigated the best method for the management of stress
hyperglycaemia. Therefore, to follow general recommendations for hospital inpatients with
hyperglycaemia is reasonable, keeping in mind that stress hyperglycaemia by definition is a
transient, often dynamic disorder that responds to changes in disease course. Specific
recommendations for implementation of glycaemic control generally include insulin
therapy, and in the surgical and medical ICU insulin infusions are favoured. Stress hyper
glycaemia lends itself ideally to insulin, which is rapidly titratable in response to changes in
glucose concentrations. Intravenous insulin is highly effective and can be adjusted
frequently. In patients with oedema or hypoperfusion, subcutaneous insulin might result in
insulin stacking and hypoglycaemia.111 However, intravenous insulin is still relegated to the
ICU in many institutions because of concerns about safety and about adequate staffing.
Subcutaneous insulin is reasonable for most general surgical and medical patients outside
the ICU. In the outpatient setting, insulin analogues usually produce a lower incidence of
hypoglycaemia than do regular human insulin or neutral protamine hagedom (NPH) insulin,
but this finding was not confirmed in an inpatient study of patients with type 2 diabetes.112
Results of another randomised controlled trial113 of insulin naive patients with diabetes
showed that subcutaneous basal bolus insulin was better than was sliding-scale insulin for
attainment of safe, effective glycaemic control. Investigators were able to safely escalate the
dose of insulin daily, but seemed to need up to 3 days to reach a target glucose of 7·8 mmol/
L. In another study114 patients who initially received intravenous insulin in the ICU and then
were rapidly transitioned to subcutaneous insulin for transfer to the wards had good
outcomes.
Carers should take steps to pre-emptively adjust therapy in response to changes in nutritional
needs. This strategy could include consistent carbohydrate diets or giving prandial insulin
according to estimated carbohydrate intake. During enteral feeding, anticipatory orders,
including increased monitoring, withholding insulin, and, if needed, dextrose infusion in
case of planned or unplanned interruption are necessary. The amount of exogenous,
intravenous, and enteral glucose given is commonly overlooked, and can be restricted when
necessary—eg, by changing enteral formulas. No prospective data show that interventions
designed specifically to reduce glucose fluctuations improve outcomes. However,
fluctuations in glucose might be kept to a minimum with physiological insulin
replacement,115,116 especially to ensure adequate carbohydrate coverage. Insulin-drip
protocols effectively provide basal and correction insulin coverage, but additional
subcutaneous short-acting insulin is usually necessary to prevent rapid glucose swings in
patients with intermittent exogenous carbohydrate exposure.117 Furthermore, proper training
and use of improved algorithms for intravenous insulin could be useful.117–120
Anticipatory reduction in total daily insulin doses of at least 10–20% are sometimes
necessary in patients with tight glucose control who are clinically improving. Experts do not
advocate the use of oral hypoglycaemic agents agents for most hospital inpatients because of
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the often slow onset and resolution of action, risk of hypoglycaemia in patients with
unpredictable nutritional intake, and because of contraindications, such as frequent
administration of contrast dye in patients taking metformin.104
Prevention and monitoring
In most patients, hospital-related hyperglycaemia is not generally predictable or preventable.
However, early recognition and interception might prevent its persistence and exacerbation.
In patients with diabetes, observational data suggest that long-term preadmission glycaemic
control might affect the operative risk for both cardiovascular and non-cardiac
complications.55,121 Furthermore, preoperative glucotoxicity could affect the ease with
which postoperative control is achieved. Although gross intraoperative hyperglycaemia
might be deleterious for certain procedures, intraoperative use of strict glycaemic control is
still controversial.56,57
The effectiveness and safety of any glycaemic intervention depends upon the ability to
accurately monitor glucose. Especially in the ICU, many confounding factors in glucose
measurement such as anaemia or hypotension might be present simultaneously, and could
render typical bedside capillary point of care devices inaccurate.122 Because of their
increased severity of illness, glucose measurement in patients with stress hyperglycaemia
can be especially challenging. Real-time continuous glucose monitoring with interstitial
glucose measurements could potentially reduce the frequency of blood glucose sampling,
but this method is even more vulnerable to error and is only ap proved for adjunctive use.123
Finally, an oral-glucose-tolerance-test or close monitoring at follow-up are needed at
discharge to identify patients with underlying diabetes and prevent subacute (eg, infectious)
or long-term complications.
Future direction and conclusion
Prospective studies with follow-up data comparing diabetes and stress hyperglycaemia are
needed. HbA1c should be reported both to exclude undiagnosed probable diabetes and to
infer whether patients with diabetes have stress-related exacerbation of hyperglycaemia.
Patients with non-diabetic stress hyperglycaemia should be compared with a subgroup of
patients with diabetes who have stress-related exacerbation of hyperglycaemia, and those
with non-diabetic normoglycaemia should be compared with those with diabetes whose
glucose control was unaltered at admission. Additionally, researchers examining risks and
outcomes of hypoglycaemia should place special emphasis on high-risk cardiac subgroups.
The optimum target glucose range in stress conditions is still undefined, and different targets
should be compared on the basis of their risk-to-benefit ratios.
Until such data are available, efforts to improve ease of use and safety of intensive
glycaemic control, such as computerised insulin dosing algorithms and glucose monitoring
techniques, might mitigate the need for risk stratification. Stress hyperglycaemia is a
heterogeneous entity with unique pathophysiological features. Present practice is to treat
hyperglyacemia irrespective of its cause. However, we suggest that the chronicity of
hyperglycaemia and other factors specific to patients or populations merits special
consideration.
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Search strategy and selection criteria
We searched PubMed with the terms “stress hyperglycemia”, “diabetes”,
“hyperglycemia” in conjunction with the key modifying terms “admission”, “hospital”,
“inpatient”, “intensive care unit”, “critical care”, “acute myocardial infarction”, and
“acute stroke”. We also searched the reference lists of reports identified with this strategy
for relevant publications. We prioritised controlled trials or meta-analyses and
observational studies from the past 5 years. We used only studies in peer-reviewed
journals, focusing on comparisons between stress hyperglycaemia and diabetes.
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Expanded view of stress hyperglycaemia
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Figure 2. Multifactorial causes of hospital-related hyperglycaemia
Causal factors are specific to the patient, their illness, and their treatment. Hyperglycaemia
can exacerbate some illness-specific factors and increase need for treatment-specific factors,
leading to a vicious cycle by which hyperglycaemia causes further hyperglycaemia.
HPA=hypothalamic-pituitary-adrenal axis.
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Figure 3. Glucose metabolism in stress hyperglycaemia
Stress hyperglycaemia is characterised by increased whole-body glucose uptake, mostly
caused by non-insulin-mediated glucose transport via GLUT-1 transporters to body tissues.
Insulin-mediated glucose uptake is reduced (insulin resistance), largely due to postreceptor
insulin signalling defects that result in reduced GLUT-4-mediated glucose transport in
insulin sensitive tissues such as liver, muscle, and fat. Muscle glycogen storage is also
reduced. Glucose production is generally up-regulated, mainly a result of unregulated
hepatic gluconeogenesis. Finally, once inside a target cell, glucose is oxidised readily but
non-oxidative metabolism (predominantly glycogen storage) is impaired.
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Figure 4. Overlapping mechanisms of harm in hyperglycaemia
Mechanisms of harm relate to acute or chronic complications of hyperglycaemia. NFkB =
nuclear factor κ B.
ERK = extracellular signal regulated kinase. MAPK=microtubule associated protein kinase.
PKC = protein kinase C.
AGE = advanced glycosylation endproducts. CVA = cerebrovascular accident. AMI = acute
myocardial infarction.
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